GNI Group
2160.TTSE GROWTHPharmaceutical
Filed as GNI Group Ltd. (2022-08–2026-08)
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥21m | ¥24mr | ¥22mr | ¥22mr | ¥225mr | ¥356m |
| Operating income | −¥662m | −¥657mr | −¥562m | −¥542m | −¥424m | — |
| Ordinary income | −¥1.9bn | ¥5.9bnr | −¥30mr | −¥552mr | −¥436mr | −¥170m |
| Total assets | ¥48.8bn | ¥39.9bnr | ¥30.6bnr | ¥15.5bnr | ¥16.5bnr | ¥11.8bn |
| Net assets / equity | ¥35.4bn | ¥24.1bnr | ¥17.7bnr | ¥14.6bnr | ¥15.7bnr | ¥10.9bn |
| EPS (basic) | ¥-34.71 | ¥118.06 | ¥-21.92 | ¥-25.5 | ¥-9.33 | ¥-3.94 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 89 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 209 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 89 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 209 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 105 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 89 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 207 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 111 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 111 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 89 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 206 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 111 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 111 figures · EDINET |
32 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Medical Device | ¥7.7bn | ¥533m |
| Pharmaceutical | ¥19.2bn | −¥4.0bn |
| Total | ¥26.8bn | −¥3.5bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.